Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication
The Oncologist · 2024
DOI: 10.1093/oncolo/oyae004 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Riccardo Giovanni Borroni und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy. Hauptthemen laut MEDLINE: Purines, Breast Neoplasms, Aminopyridines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Ribociclib is approved for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) advanced breast cancer (ABC) treatment, in combination with endocrine therapy. Hematological, hepatic, and cardiac adverse events (AEs) emerged from pivotal trials, but little is known about cutaneous adverse events (CAEs). Patients and Methods We report data from a retrospective cohort study of all patients with HR+/HER2− ABC treated with ribociclib at Humanitas Cancer Center between June 2017 and December 2022. We recorded clinical-pathological data, the incidence, and treatment of ribociclib-related CAEs. These were evaluated according to the NCI-CTCAE v5.0 classification. Progression-free survival (PFS) was estimated by Kaplan-Meier method and the log-rank test was used to analyze differences between groups.
Results
Thirteen of 91 patients (14.3%) experienced treatment-related CAEs (mean time to the occurrence: 3.9 months). The most frequent CAEs were eczematous dermatitis (53.8%) and maculo-papular reaction (15.4%). Itch was reported by all 13 patients. The grade was G3 in 8 cases, G2 in 4, and G1 in 1. An integrated approach based on ribociclib dose modulation and dermatological interventions (oral antihistamine, moisturized cream, topical, and/or systemic steroids) could prevent ribociclib discontinuation in most patients. At a median follow-up of 20 months, the median PFS was 13 months (range, 1-66) with a better PFS curves for patients experiencing CAEs (P = .04).
Conclusion
We mapped frequency and types of ribociclib-induced CAEs. An interdisciplinary management of CAEs incorporated into routine care may reduce the rate of drug discontinuation thus potentially contributing to better long-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy.
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy.
- Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy.
- Pathology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy.
ORCID-Profile: Rita De Sanctis
Zitieren
APA
Borroni, R. G., Bartolini, M., Gaudio, M., Jacobs, F., Benvenuti, C., Gerosa, R., Tiberio, P., Manara, S. A. A. M., Solferino, A., Santoro, A., & De Sanctis, R. (2024). Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication. The Oncologist. https://doi.org/10.1093/oncolo/oyae004
Vancouver
Borroni RG, Bartolini M, Gaudio M, Jacobs F, Benvenuti C, Gerosa R, et al. Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication. The Oncologist. 2024. doi:10.1093/oncolo/oyae004
BibTeX
@article{Borroni2024,
author = {Borroni, Riccardo Giovanni and Bartolini, Michela and Gaudio, Mariangela and Jacobs, Flavia and Benvenuti, Chiara and Gerosa, Riccardo and Tiberio, Paola and Manara, Sofia Ada Assunta Maria and Solferino, Alessandra and Santoro, Armando and De Sanctis, Rita},
title = {Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2− Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyae004}
}
EUVIMED